RxDoctor Payments Data

Daniel Kellum, DO

Family Medicine · San Antonio, TXNPI 1174518625

Payments from drug & device makers

$12,343in general payments, 2019–2025

Across 948 payments — averaging $13.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Merck$683
  • AstraZeneca$591
  • Bayer$557
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$490
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$12,318100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)366$3,090
Novo Nordisk111$1,511
Merck57$683
AstraZeneca27$591
Bayer45$557
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)36$490
Boehringer Ingelheim24$415
GSK18$307
Pfizer20$293
Avanir Pharmaceuticals, Inc.18$292
Lilly USA, LLC16$277
Sanofi-aventis U.S. LLC12$272
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$269
Johnson & Johnson15$264
Sunovion Pharmaceuticals Inc.13$241
Sumitomo Pharma America, Inc.10$208
Mayne Pharma Commercial LLC2$185
Novartis11$172
Axsome Therapeutics, Inc.9$147
Ironwood Pharmaceuticals, Inc9$132
Daiichi Sankyo Inc.7$111
Abbott6$104
Amgen(2 entities)7$102
Biohaven Pharmaceutical Holding Company Ltd.4$87
Supernus Pharmaceuticals, Inc.4$86
Astellas Pharma US Inc5$84
Medtronic1$84
Kowa Pharmaceuticals America, Inc.5$81
Ardelyx, Inc.4$80
Shield Therapeutics Inc4$70
Biohaven Pharmaceuticals, Inc.3$69
Ironshore Pharmaceuticals Inc.5$67
Collegium Pharmaceutical, Inc.4$63
Corcept Therapeutics3$59
Nestle Healthcare Nutrition Inc.3$57
Genentech USA, Inc.3$57
Esperion Therapeutics, Inc.4$55
Smith+Nephew3$47
Takeda Pharmaceuticals U.S.A., Inc.3$41
Exact Sciences2$40
Dexcom, Inc.2$40
Amarin Pharma, Inc.3$39
Corium, LLC2$36
Otsuka America Pharmaceutical, Inc.2$35
Currax Pharmaceuticals LLC2$33
Vanda Pharmaceuticals Inc.2$32
Zealand Pharma US, Inc.1$26
Impel Pharmaceuticals Inc.1$25
Si-bone, Inc.1$24
Itamar Medical Inc1$24
Azurity Pharmaceuticals, Inc.1$19
Alk-abello, Inc1$18
Aimmune Therapeutics, Inc.1$18
Seqirus USA Inc1$17
Lundbeck LLC1$16
Antares Pharma, Inc.1$15
Lifescan, Inc.1$15
Intuitive Surgical1$13
Teva Pharmaceuticals USA, Inc.1$13
VBI Vaccine (delaware) Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,343 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,797
Medicare patients
238
Services billed
2,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide178$203,125
TrulicityDulaglutide140$189,686
OzempicSemaglutide162$181,059
JardianceEmpagliflozin138$175,641
FarxigaDapagliflozin Propanediol98$104,675
JanuviaSitagliptin Phosphate94$103,567
EliquisApixaban131$102,359
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$73,522
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog68$53,343
Tresiba Flextouch U-200Insulin Degludec54$50,901
LinzessLinaclotide56$46,797
EntrestoSacubitril/Valsartan50$43,572
GemtesaVibegron67$43,245
GlyxambiEmpagliflozin/Linagliptin25$28,093
TradjentaLinagliptin27$25,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$277$392,811318 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Jentadueto, Synjardy$415$255,708212 claims
Novo NordiskOzempic, Rybelsus$1,511$202,867178 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$591$134,265157 claims
MerckJanuvia, Janumet$683$124,521109 claims
PfizerEliquis$293$102,359131 claims
AbbVieLinzess, Vraylar, Creon$3,090$82,81089 claims
GSKTrelegy Ellipta$307$73,52293 claims
NovartisEntresto$172$43,57250 claims
Sumitomo Pharma America, Inc.Gemtesa$208$43,24567 claims
Astellas Pharma US IncMyrbetriq$84$20,38332 claims
Johnson & JohnsonXarelto$264$18,03825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →